

1 **Longitudinal assessment of diagnostic test performance over the course of acute SARS-**
2 **CoV-2 infection**

3
4 **Rebecca L. Smith^{1,2,3*}, Laura L. Gibson⁴, Pamela P. Martinez^{1,5,6}, Ruian Ke⁷, Agha Mirza⁸,**
5 **Madison Conte⁸, Nicholas Gallagher⁹, Abigail Conte¹⁰, Leyi Wang¹¹, Rick Fredrickson¹¹,**
6 **Darci C. Edmonson¹, Melinda E. Baughman¹, Karen K. Chiu¹, Hannah Choi¹, Tor W.**
7 **Jensen^{1,12}, Kevin R. Scardina¹, Shannon Bradley¹, Stacy L. Gloss¹, Crystal Reinhart¹,**
8 **Jagadeesh Yedetore¹, Alyssa N. Owens¹³, John Broach^{14,15}, Bruce Barton^{16,17}, Peter**
9 **Lazar¹⁶, Darcy Henness¹⁸, Todd Young¹⁸, Alastair Dunnett¹⁸, Matthew L. Robinson⁸, Heba**
10 **H. Mostafa⁹, Andrew Pekosz¹⁰, Yukari C. Manabe⁸, William J. Heetderks¹⁹, David D.**
11 **McManus²⁰, Christopher B. Brooke^{1,5*}**

12
13 ¹ Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign,
14 Urbana, IL

15 ² Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL

16 ³ Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL

17 ⁴ Division of Infectious Diseases and Immunology, Departments of Medicine and Pediatrics,
18 University of Massachusetts Medical School, Worcester, MA

19 ⁵ Department of Microbiology, University of Illinois at Urbana-Champaign, Urbana, IL

20 ⁶ Department of Statistics, University of Illinois at Urbana-Champaign, Urbana, IL

21 ⁷ T-6, Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM.

22 ⁸ Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine,
23 Baltimore, MD

24 ⁹ Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School
25 of Medicine, Baltimore, MD

26 ¹⁰ W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins
27 Bloomberg School of Public Health, Baltimore, MD

28 ¹¹ Veterinary Diagnostic Laboratory, University of Illinois at Urbana-Champaign, Urbana, IL

29 ¹² Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL

30 ¹³ Center for Clinical and Translational Research, University of Massachusetts Medical School,
31 Worcester, MA

32 ¹⁴ UMass Memorial Medical Center, Worcester, MA

33 ¹⁵ Department of Emergency Medicine, University of Massachusetts Medical School, Worcester,
34 MA

35 ¹⁶ Division of Biostatistics and Health Services Research, University of Massachusetts Medical
36 School, Worcester, MA

37 ¹⁷ Department of Population and Quantitative Health Sciences, University of Massachusetts
38 Medical School, Worcester, MA

39 ¹⁸ Carle Foundation Hospital, Urbana, IL

40 ¹⁹ National Institute for Biomedical Imaging and Bioengineering, Bethesda, MD

41 ²⁰ Division of Cardiology, University of Massachusetts Medical School, Worcester, MA

42
43 * Corresponding authors (rlsdvm@illinois.edu, cbrooke@illinois.edu)

46 **SUMMARY:**

47 **What is already known about this topic?**

48 Diagnostic tests and sample types for SARS-CoV-2 vary in sensitivity across the infection
49 period.

50

51 **What is added by this report?**

52 We show that both RTqPCR (from nasal swab and saliva) and the Quidel SARS Sofia FIA rapid
53 antigen tests peak in sensitivity during the period in which live virus can be detected in nasal
54 swabs, but that the sensitivity of RTqPCR tests rises more rapidly in the pre-infectious period.
55 We also use empirical data to estimate the sensitivities of RTqPCR and antigen tests as a
56 function of testing frequency.

57

58 **What are the implications for public health practice?**

59 RTqPCR tests will be more effective than rapid antigen tests at identifying infected individuals
60 prior to or early during the infectious period and thus for minimizing forward transmission
61 (provided results reporting is timely). All modalities, including rapid antigen tests, showed >94%
62 sensitivity to detect infection if used at least twice per week. Regular surveillance/screening
63 using rapid antigen tests 2-3 times per week can be an effective strategy to achieve high
64 sensitivity (>95%) for identifying infected individuals.

65

66 **INTRODUCTION:**

67 Frequent rapid diagnostic testing is critical for restricting community spread of SARS-CoV-2 by
68 allowing the timely identification and isolation of infected individuals to interrupt the chain of
69 transmission. Quantitative reverse transcription polymerase chain reaction (RTqPCR)-based
70 detection of viral RNA within nasal swab or saliva samples represents the gold standard for
71 sensitivity in detecting the presence of SARS-CoV-2, yet supply shortages, cost, and
72 infrastructure limitations have made it difficult to achieve high testing frequency and volume with
73 the rapid reporting of results needed to mitigate transmission effectively.

74

75 Recently, there has been considerable interest in the potential of rapid antigen tests to expand
76 diagnostic testing capacity due to the ease of use, availability, cost, and rapid time-to-results¹.
77 However, data for their use in screening asymptomatic individuals is sparse. Enthusiasm for
78 their widespread deployment has been further tempered by well-publicized examples of false
79 positive results in people with low pre-test probability of infection, and by reports suggesting
80 they lack sensitivity compared with RTqPCR, potentially making them less effective at mitigating
81 community spread^{2,3}.

82

83 Here, we compare the sensitivities of nasal and saliva RTqPCR tests with the Quidel Sofia
84 SARS Antigen Fluorescent Immunoassay (FIA) over the course of mild or asymptomatic acute
85 SARS-CoV-2 infection through daily sampling of individuals enrolled early during infection.

86

87 **METHODS:**

88 This study was approved by the Western Institutional Review Board, and all participants
89 consented freely.

90

91 ***Participants***

92 All on-campus students and employees of the University of Illinois at Urbana-Champaign are
93 required to submit saliva for RTqPCR testing every 2-4 days as part of the SHIELD campus
94 surveillance testing program. Those testing positive are instructed to isolate, and were eligible to
95 enroll in this study for a period of 24 hours following receipt of their positive test result. Close

96 contacts of individuals who test positive (particularly those co-housed with them) are instructed
97 to quarantine and were eligible to enroll for up to 5 days after their last known exposure to an
98 infected individual. All participants were also required to have received a negative saliva
99 RTqPCR result 7 days prior to enrollment.

100
101 Individuals were recruited via either a link shared in an automated text message providing
102 isolation information sent within 30 minutes of a positive test result, a call from a study recruiter,
103 or a link shared by an enrolled study participant or included in information provided to all
104 quarantining close contacts. In addition, signs were used at each testing location and a website
105 was available to inform the community about the study.

106
107 Participants were required to be at least 18 years of age, have a valid university ID, speak
108 English, have internet access, and live within 8 miles of the university campus. After enrollment
109 and consent, participants completed an initial survey to collect information on demographics and
110 health history, including suspected date of SARS-CoV-2 exposure. They were then provided
111 with sample collection supplies.

112
113 Participants who tested positive prior to enrollment or during quarantine were followed for up to
114 14 days. Quarantining participants who continued to test negative by saliva RTqPCR were
115 followed for up to 7 days after their last exposure. All participants' data and survey responses
116 were collected in the Eureka digital study platform.

117 118 **Sample collection**

119 Each day, participants were remotely observed by study staff collecting:

- 120 1. 2 mL of saliva into a 50mL conical tube.
- 121 2. 1 nasal swab from a single nostril using a foam-tipped swab that was placed within a dry
122 collection tube.
- 123 3. 1 nasal swab from the other nostril using a flocked swab that was subsequently placed
124 in a collection vial containing viral transport media (VTM).

125
126 The order of nostrils (left vs. right) used for the two different swabs was randomized. For nasal
127 swabs, participants were instructed to insert the soft tip of the swab at least 1 cm into the
128 indicated nostril until they encountered mild resistance, rotate the swab around the nostril 5
129 times, leaving it in place for 10-15 seconds. After daily sample collection, participants completed
130 a symptom survey. A courier collected all participant samples within 1 hour of collection using a
131 no-contact pickup protocol designed to minimize courier exposure to infected participants.

132 133 **Saliva RTqPCR**

134 After collection, saliva samples were stored at room temperature and RTqPCR was run within
135 12 hours of initial collection. The protocol for direct saliva-to-RTqPCR assay used has been
136 detailed previously⁴. In brief, saliva samples were heated at 95°C for 30 minutes, followed by
137 the addition of 2X TBS at a 1:1 ratio (final concentration 1X TBE) and Tween-20 to a final
138 concentration of 0.5%. Samples were assayed using the Thermo Taqpath COVID-19 assay.

139 140 **Quidel assay**

141 Foam-tipped nasal swabs were placed in collection tubes and stored at 4°C overnight based on
142 guidance from the manufacturer. The morning after collection, swabs were run through the Sofia
143 SARS antigen FIA on Sofia 2 devices according to the manufacturer's protocol.

144 145 **Nasal swab RTqPCR**

146 Collection tubes containing VTM and flocked nasal swabs were stored at -80°C after collection
147 and were subsequently shipped to Johns Hopkins University for RTqPCR and virus culture
148 testing. After thawing, VTM was aliquoted for RTqPCR and infectivity assays. One ml of VTM
149 from the nasal swab was assayed on the Abbott Alinity per manufacturer’s instructions in a
150 College of American Pathologist and CLIA-certified laboratory.

151

152 ***Nasal virus culture***

153 VeroTMPRSS2 cells were grown in complete medium (CM) consisting of DMEM with 10% fetal
154 bovine serum (Gibco), 1 mM glutamine (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 100
155 U/ml of penicillin (Invitrogen), and 100 µg/ml of streptomycin (Invitrogen)⁵. Viral infectivity was
156 assessed on VeroTMPRSS2 cells as previously described using infection media (IM; identical to
157 CM except the FBS is reduced to 2.5%)⁶. When a cytopathic effect was visible in >50% of cells
158 in a given well, the supernatant was harvested. The presence of SARS-CoV-2 was confirmed
159 through RTqPCR as described previously by extracting RNA from the cell culture supernatant
160 using the Qiagen viral RNA isolation kit and performing RTqPCR using the N1 and N2 SARS-
161 CoV-2-specific primers and probes in addition to primers and probes for human RNaseP gene
162 using synthetic RNA target sequences to establish a standard curve⁷.

163

164 ***Data Analysis***

165 At the time of analysis, nasal samples from 30 participants had been analyzed by virus culture
166 and RTqPCR. Therefore, analyses that consider either nasal RTqPCR or viral culture results
167 were conducted based on a limited participant set. All confidence intervals around sensitivity
168 were calculated using binconf from the Hmisc package in R version 3.6.2.

169

170 The sensitivity of each of the tests was analyzed in three different ways:

171 First, the ability of each test (antigen, saliva RTqPCR, or nasal RTqPCR) to detect an infected
172 person on a particular day relative to the day of first positive viral culture (“daily sensitivity”) was
173 calculated. Daily sensitivity was not calculated for timepoints with fewer than 5 observed
174 person-days.

175

176 Second, the ability of each test to detect an infected person according to their viral culture status
177 (“status sensitivity”) was calculated. Viral culture status was defined as “pre-positive” on days
178 prior to the first positive viral culture result, “positive” on days for which viral culture results were
179 positive, and “post-positive” on days with negative viral culture results that occur after the first
180 positive culture result. Status sensitivity was defined as the proportion of person-days with a
181 positive result.

182

183 Finally, we calculated the ability of repeated testing over a 14-day period to detect an infected
184 person (“protocol sensitivity”) using a value-of-information approach. Seven different testing
185 frequencies were considered: daily, every other day, every third day, and so on, up to weekly
186 sampling. For each individual, the result of testing on a given schedule was calculated for each
187 potential starting date, with test results interpreted in parallel (all tests must be negative to be
188 considered negative). For instance, each person contributed two observations to the “every
189 other day” schedule, one starting on the first day of the study and the other starting on the
190 second day of the study. The proportion of “observations” with a positive result (at least one
191 positive test in the sampling timeframe) was considered to be the sensitivity of that testing
192 protocol (test and frequency combination).

193

194 All code used in analyses can be found here: <https://github.com/rlsdvm/CovidDetectAnalysis>

195

196 **Results**

197 Table 1 shows demographic information for study participants reported here. The majority of
198 participants (21/30, 70%) were non-Hispanic white and the average age was 32.50 (SD 12.29).

199

200 **Table 1: Demographic information on participants enrolled in the COVID detect study**

201

| Variable | | Data |
|-------------------------------------|------------------|----------------|
| | | n=30 |
| Weight (mean (SD)) | | 176.00 (51.17) |
| Height in inches (mean (SD)) | | 67.57 (4.94) |
| Age (mean (SD)) | | 32.50 (12.29) |
| Race (%) | Native American | 0 (0.0) |
| | Asian | 1 (3.3) |
| | Black | 2 (6.7) |
| | Other | 3 (10.0) |
| | Pacific Islander | 0 (0.0) |
| | White | 24 (80.0) |
| Gender (%) | Female | 12 (40.0) |
| | Male | 18 (60.0) |
| Ethnicity (%) | Hispanic | 6 (20.0) |
| | Non-Hispanic | 24 (80.0) |

202

203 We first estimated the daily sensitivities of nasal and saliva RTqPCR and antigen tests relative
204 to the day of first nasal swab viral culture positivity, which was used as a surrogate marker of
205 infectious virus shedding (**Table 2, Figure 1**). We also used the viral culture data to measure
206 the status sensitivities of each test before, during, and after viral shedding (**Figure 2**).

207

208 Prior to the first day of detectable shedding of infectious virus, both RTqPCR tests had higher
209 daily sensitivity (0.706 for both saliva and nasal) than the antigen test (0.412). For all three
210 tests, daily and status sensitivity peaked during days in which infectious virus shedding was
211 detectable, as would be expected. Antigen test daily sensitivity declined precipitously after
212 infectious virus could no longer be detected in nasal swabs, dropping below 0.5 within a week
213 after the onset of culture positivity, while both nasal and saliva RTqPCR platforms only showed
214 minor decreases in sensitivity, remaining at 0.792 and 0.667 after a week, respectively.

215


216

217 **Table 2: Daily sensitivity of each test platform by day relative to the day of first nasal**
 218 **swab viral culture positivity.**
 219


| Days before (-1,-2), on (0), or after the day of first positive culture | Antigen | | Saliva RTqPCR | | Nasal RTqPCR | | Total |
|---|-------------------|-----------------|-------------------|-----------------|-------------------|-----------------|-------|
| | Daily Sensitivity | Number positive | Daily Sensitivity | Number positive | Daily Sensitivity | Number positive | |
| -2 | 0.333 | 2 | 0.833 | 5 | 0.667 | 4 | 6 |
| -1 | 0.455 | 5 | 0.636 | 7 | 0.727 | 8 | 11 |
| 0 | 0.875 | 21 | 0.958 | 23 | 1.000 | 24 | 24 |
| 1 | 0.960 | 24 | 1.000 | 25 | 1.000 | 25 | 25 |
| 2 | 0.960 | 24 | 0.960 | 24 | 1.000 | 25 | 25 |
| 3 | 0.920 | 23 | 0.920 | 23 | 1.000 | 25 | 25 |
| 4 | 0.760 | 19 | 0.960 | 24 | 1.000 | 25 | 25 |
| 5 | 0.640 | 16 | 0.840 | 21 | 0.960 | 24 | 25 |
| 6 | 0.560 | 14 | 0.920 | 23 | 0.880 | 22 | 25 |
| 7 | 0.250 | 6 | 0.667 | 16 | 0.792 | 19 | 24 |
| 8 | 0.182 | 4 | 0.682 | 15 | 0.909 | 20 | 22 |
| 9 | 0.045 | 1 | 0.500 | 11 | 0.727 | 16 | 22 |
| 10 | 0 | 0 | 0.500 | 10 | 0.900 | 18 | 20 |
| 11 | 0.05 | 1 | 0.500 | 10 | 0.800 | 16 | 20 |
| 12 | 0 | 0 | 0.368 | 7 | 0.526 | 10 | 19 |
| 13 | 0 | 0 | 0.231 | 3 | 0.385 | 5 | 13 |

220
221

222 **Figure 1: Daily sensitivity of each test platform by day relative to the day of first positive**
223 **viral culture result. Shaded areas represent the 95% confidence interval around the observed**
224 **proportion.**



225 **Figure 2: Status sensitivity of each test platform relative to viral culture positivity. Bars**
226 **indicate the 95% confidence interval around the observed proportion. Pre-positive (n=29) refers**
227 **to samples taken on days before the first viral culture-positive sample collected from each**
228 **individual. Positive (n=127) refers to samples taken on days for which viral culture results were**
229 **positive. Post-positive (n=112) refers to samples taken on days with negative viral culture**
230 **results that occur after the first positive culture result.**
231
232
233



234

235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250


We next estimated the protocol sensitivities, or how the ability of each of test platform to detect infected individuals was affected by differences in testing frequencies (**Table 3, Figure 3**). Protocol sensitivity was defined at the schedule level, where the numerator is the number of testing schedules resulting in at least one positive test and the denominator is the number of testing schedules examined, where a testing schedule is defined as a set of samples from one participant taken at a given frequency. In **Figure 3**, we calculated the effects of varying testing frequency on sensitivity to detect infected individuals on days where nasal swabs were viral culture positive in the top panel. In the bottom panel of **Figure 3**, we examined sensitivity to detect infected individuals at any stage of infection.

Table 3: Protocol sensitivity of each test platform to detect an infected person during a 14-day testing period, relative to the frequency of testing. “Any time” refers to detection of the individual at any point in the 14-day testing period; “While VC+” refers to detection of the individual before or during the time in which their viral culture was positive.

| Testing Frequency | N | Nasal Antigen | | | | Saliva RTqPCR | | | | Nasal RTqPCR | | | |
|-------------------|-----|--------------------------|-----------|-----------------|-----------|--------------------------|-----------|-----------------|-----------|--------------------------|-----------|-----------------|-----------|
| | | Probability of Detection | | Number Positive | | Probability of Detection | | Number Positive | | Probability of Detection | | Number Positive | |
| | | Any time | While VC+ | Any time | While VC+ | Any time | While VC+ | Any time | While VC+ | Any time | While VC+ | Any time | While VC+ |
| Daily | 34 | 1.000 | 0.941 | 34 | 32 | 1.000 | 0.971 | 34 | 33 | 1.000 | 1.000 | 34 | 34 |
| Every Other Day | 68 | 0.971 | 0.824 | 66 | 56 | 0.956 | 0.853 | 65 | 58 | 0.985 | 0.882 | 67 | 60 |
| Every Third Day | 102 | 0.961 | 0.794 | 98 | 81 | 0.941 | 0.814 | 96 | 83 | 0.98 | 0.843 | 100 | 86 |
| Every Fourth Day | 136 | 0.912 | 0.721 | 124 | 98 | 0.934 | 0.743 | 127 | 101 | 0.971 | 0.772 | 132 | 105 |
| Every Fifth Day | 170 | 0.888 | 0.641 | 151 | 109 | 0.924 | 0.676 | 157 | 115 | 0.971 | 0.712 | 165 | 121 |
| Every Sixth Day | 204 | 0.833 | 0.569 | 170 | 116 | 0.907 | 0.608 | 185 | 124 | 0.956 | 0.632 | 195 | 129 |
| Weekly | 238 | 0.761 | 0.508 | 181 | 121 | 0.903 | 0.546 | 215 | 130 | 0.958 | 0.571 | 228 | 136 |

251
252

253 **Figure 3: Protocol sensitivity of each test platform to detect an infected person (top) before**
 254 **or during days where nasal samples were viral culture positive or (bottom) at any time, over a**
 255 **14-day testing period, relative to frequency of testing. Lines indicate 95% confidence interval**
 256 **around the observed proportion.**
 257



258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269

Discussion

Our data indicate that RTqPCR and antigen tests vary significantly over the course of SARS-CoV-2 infection. Prior to the infectious period (here defined as the period during which infectious virus could be detected in nasal swab samples), the daily sensitivities of nasal and saliva RTqPCR tests were higher than that of the Quidel Sofia SARS Antigen FIA, suggesting that RTqPCR tests will be more effective at identifying infected individuals before they transmit to others.

Both RTqPCR and antigen tests peak in daily and status sensitivities when infectious virus is detectable in nasal swab samples, suggesting that all three modalities can be effective at

270 identifying individuals during the infectious period. After this period, the daily sensitivity of
271 RTqPCR tests decreased gradually, with saliva RTqPCR dropping faster than nasal RTqPCR.
272 These dynamics are consistent with those described previously for RTqPCR^{8,9}. In contrast, the
273 daily sensitivity of the antigen test declined very quickly, suggesting that this test will be less
274 effective at identifying individuals during later stages of infection. This may limit diagnosis and
275 contact-tracing efforts in test-limited environments.

276
277 Previous studies have suggested that frequent testing would maximize the ability of a given test
278 modality to detect infected individuals^{10,11}. We found that all testing modalities showed almost
279 95% protocol sensitivity to detect infection if used at least twice per week. When applied weekly,
280 protocol sensitivity remained very high for nasal RTqPCR, declined slightly to 90% for saliva
281 RTqPCR, and dropped to only 76% for the antigen test.

282
283 When we compared the abilities of different testing frequencies to identify individuals while
284 infectious virus was detectable in nasal samples, we observed a clear reduction in protocol
285 sensitivity for all testing modalities when testing frequencies decreased below daily. The
286 reduction in protocol sensitivity was most pronounced for the antigen test, which dropped to
287 0.72 with testing every fourth day, however, both RTqPCR tests were only slightly better at 0.74
288 (saliva) and 0.77 (nasal). Altogether, these data demonstrate the importance of frequent testing
289 regardless of test modality for identifying individuals while they are contagious.

290
291 This is the first study to compare the longitudinal performance of rapid antigen and RTqPCR
292 tests with infectious virus shedding in a well-defined population early in SARS-CoV-2 infection.
293 We found that all three diagnostic tests demonstrated a high degree of daily sensitivity during
294 the presumed infectious period, but that the RTqPCR tests exhibited superior daily sensitivities
295 prior to this period. Our data suggest that RTqPCR tests can be more effective than antigen
296 tests at mitigating community spread of SARS-CoV-2, but only if the turnaround time for
297 RTqPCR results is short. Finally, these data also quantitatively demonstrate the importance of
298 frequent (at least twice per week) screening to maximize likelihood of detecting infected
299 individuals regardless of testing modality.

300 301 **Acknowledgments**

302 This study was funded by the NIH RADx-Tech program under 3U54HL143541-02S2. The views
303 expressed in this manuscript are those of the authors and do not necessarily represent the
304 views of the National Institute of Biomedical Imaging and Bioengineering; the National Heart,
305 Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health
306 and Human Services. Sofia 2 devices and associated supplies were provided to Carle
307 Foundation Hospital by Quidel, however Quidel played no role in the design of the study or the
308 interpretation or presentation of the data.

309
310 We also thank Shumon Ahmed, Carly Bell, Nate Bouton, Callie Brennen, Justin Brown, Coleco
311 Buie, Emmaline Cler, Gary Cole, Trey Coleman, Lauren Engels, Savannah Feher, Kelsey Fox,
312 Lexi Freeman, Yesenia Gonzalez, Montez Harris, Dan Hiser, Ayeshah Hussain, Daryl Jackson,
313 Michael Jenkins, Kalombo Kalonji, Syntyche Kanku, Steven Krauklis, Mary Krouse, Elmore
314 Leshoure, Joe Lewis, Angel Lopez, Guadalupe Lopez, Emily Luna, Chun Huai Luo, Colby
315 Mackey, Skyler McLain, Yared Berhanu Melesse, Madison O'Donnell, Savanna Pflugmacher,
316 Denver Piatt, Skyler Pierce, Jessica Quicksall, Gina Quitanilla, Ameera Samad, MacKenzie
317 Scroggins, Monique Settles, Macie Sinn, Pete Varney, Evette Vlach, and Raeshun Williams-
318 Chatman for their efforts supporting recruitment, enrollment, logistics, and sample
319 collection. We also thank Jeffrey Olgin, Noah Peyser, and Xochitl Butler for assistance with the

320 Eureka platform, Michelle Lore for assistance with REDcap, and Gillian Snyder for assistance in
321 development of study protocols and logistics.

322

323 References

324 1. Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, Schnitzler P,
325 Kräusslich HG, Lindner AK, Nikolai O, Mockenhaupt FP, Seybold J, Corman VM, Drosten
326 C, Pollock NR, Cubas-Atienzar AI, Kontogianni K, Collins A, Wright AH, Knorr B, Welker A,
327 de Vos M, Sacks JA, Adams ER, Denkinger CM, for the study team. Evaluation of the
328 accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care
329 diagnostics for *SARS-CoV-2* [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 Oct.
330 Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.10.01.20203836>

331 2. Jääskeläinen A, Ahava M, Jokela P, Szivovics L, Pohjala S, Vapalahti O, Lappalainen M,
332 Hepojoki J, Kurkela S. Evaluation of three rapid lateral flow antigen detection tests for the
333 diagnosis of SARS-CoV-2 infection [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2021
334 Jan. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.12.30.20249057>

335 3. Moreno GK, Braun KM, Pray IW, Seagaloff HE, Lim A, Poulsen K, Meiman J, Borchers J,
336 Westergaard RP, Moll MK, Friedrich T, O'Connor DH. SARS-CoV-2 transmission in
337 intercollegiate athletics not fully mitigated with daily antigen testing [Internet]. *Infectious
338 Diseases (except HIV/AIDS)*; 2021 Mar. Available from:
339 <http://medrxiv.org/lookup/doi/10.1101/2021.03.03.21252838>

340 4. Ranoa DRE, Holland RL, Alnaji FG, Green KJ, Wang L, Brooke CB, Burke MD, Fan TM,
341 Hergenrother PJ. Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA
342 Extraction [Internet]. *Microbiology*; 2020 Jun. Available from:
343 <http://biorxiv.org/lookup/doi/10.1101/2020.06.18.159434>

344 5. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T,
345 Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T,
346 Kageyama T, Takeda M. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing
347 cells. *Proc Natl Acad Sci U S A*. 2020 Mar 31;117(13):7001–7003. PMID: PMC7132130

348 6. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsí S, Gary DS, Roger-Dalbert C,
349 Leitch J, Cooper CK. Antigen-Based Testing but Not Real-Time Polymerase Chain
350 Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture.
351 *Clin Infect Dis*. 2021 Jan 20; PMID: PMC7929138

352 7. Waggoner JJ, Stittleburg V, Pond R, Saklawi Y, Sahoo MK, Babiker A, Hussaini L, Kraft
353 CS, Pinsky BA, Anderson EJ, Roupheal N. Triplex Real-Time RT-PCR for Severe Acute
354 Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2020 Jul;26(7):1633–1635.

355 8. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott
356 IM, Vogels CBF, Wohlgenuth J, Weisberger J, DiFiori J, Anderson DJ, Mancell J, Ho DD,
357 Grubaugh ND, Grad YH. SARS-CoV-2 viral dynamics in acute infections [Internet].
358 *Epidemiology*; 2020 Oct. Available from:
359 <http://medrxiv.org/lookup/doi/10.1101/2020.10.21.20217042>

360 9. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, Butler F, Griffin J, Lane EA,
361 McAloon C, O'Brien K, Wall P, Walsh KA, More SJ. Inferred duration of infectious period of
362 SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic
363 and symptomatic COVID-19 cases. *BMJ Open*. 2020 Aug;10(8):e039856.

364 10. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to
365 Permit the Safe Reopening of College Campuses in the United States. *JAMA Netw Open*.
366 2020 Jul 31;3(7):e2016818.

367 11. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ,
368 Parker R. Test sensitivity is secondary to frequency and turnaround time for COVID-19
369 screening. *Sci Adv*. 2021 Jan;7(1):eabd5393.

370